Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial Cancers
May 17th 2019Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.
Watch
Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC
May 16th 2019Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib with a 160 mg dose in patients with <em>EGFR</em>-positive advanced non–small cell lung cancer with leptomeningeal metastases.
Watch
Reviewing Key Points from the Phase III MURANO Trial in CLL
May 11th 2019William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.
Watch
Highlighting Latest Additions to the Treatment Landscape for AML
May 8th 2019Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.
Watch